DelveInsight has launched a new report on Alzheimer’s disease (AD) – Epidemiology Forecast to 2030
DelveInsight’s ‘Alzheimer’s disease (AD) – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Alzheimer’s disease (AD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the key facts of the Report:
- It is estimated that 5 million Americans aged 65 years or older had Alzheimer’s disease. This number is projected to nearly triple to 14 million people by 2060.
- Delveinsight estimates are based on the age of onset, AD is classified into early-onset AD (EOAD, onset 95% of affected (2014).
- AD affects an estimated 6.08 million people in the US, and approximately 200,000 people younger than 65 years with AD constitute the younger-onset US population with AD [2019].
Request for Sample Pages https://www.delveinsight.com/sample-request/alzheimers-disease-ad-epidemiology-forecast
“According to DelveInsight, more women than men have Alzheimer’s or other dementias.”
Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. It is the most common cause of dementia (a continuous decline in thinking, behavioral and social skills that disrupts a person’s ability to function independently) accounting for ~60–80% of cases.
The exact cause of Alzheimer’s disease is unknown, although a number of things are thought to increase your risk of developing the condition. These include increasing age, a family history of the condition, previous severe head injuries, and lifestyle factors and conditions associated with cardiovascular disease. The most common early symptom of Alzheimer’s is difficulty in remembering newly learned information because Alzheimer’s changes typically begin in that part of the brain that affects learning.
In most people with Alzheimer’s, symptoms first appear in their mid-60s. On the basis of severity, Alzheimer’s disease can be classified as mild, moderate, and severe.
“As per DelveInsight’s Analysis, Alzheimer’s is the sixth leading cause of death in the United States.”
Scope of the Report
- The Alzheimer’s disease (AD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Alzheimer’s disease (AD) Epidemiology Report and Model provide an overview of the risk factors and global trends of Alzheimer’s disease (AD) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight about the historical and forecasted patient pool of Alzheimer’s disease (AD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Alzheimer’s disease (AD)
- The report provides the segmentation of the Alzheimer’s disease (AD) epidemiology
KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Request a Free Sample Report @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-epidemiology-forecast
Key Questions Answered
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Alzheimer’s disease (AD)?
- What are the key findings pertaining to the Alzheimer’s disease (AD) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
- What would be the total number of patients of Alzheimer’s disease (AD) across the 7MM during the forecast period (2017-2030)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
- What is the disease risk, burden and unmet needs of the Alzheimer’s disease (AD)?
- What are the currently available treatments of Alzheimer’s disease (AD)?
Reasons to buy
- The Alzheimer’s disease (AD) Epidemiology report will allow the user to –
- Develop business strategies by understanding the trends shaping and driving the global Alzheimer’s disease (AD) market
- Quantify patient populations in the global Alzheimer’s disease (AD) market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Alzheimer’s disease (AD) therapeutics in each of the markets covered
- Understand the magnitude of Alzheimer’s disease (AD) population by its epidemiology
- The Alzheimer’s disease (AD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Related Reports:
Alzheimer’s disease – Pipeline Insights, 2020
The Alzheimer’s disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Alzheimer’s disease across the complete product development cycle, including all clinical and nonclinical stages.
Alzheimer’s disease (AD)- Market Insight, Epidemiology and Market Forecast -2030
The Alzheimer’s disease (AD) market report provides current treatment practices, emerging drugs, Alzheimer’s disease (AD) market share of the individual therapies, current and forecasted Alzheimer’s disease (AD) market Size from 2017 to 2030 segmented by seven major markets.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/